ANNXAnnexon, Inc.

GBS and geographic atrophy programs advance toward 2026-2027 regulatory submissions.

Annexon (ANNX) stock was in focus after the company updated investors on its late stage pipeline, highlighting a dual primary endpoint for the Phase 3 ARCHER II trial and new Guillain Barré syndrome data. See our latest analysis for Annexon. Against this backdrop of clinical updates and financing activity, Annexon’s share price has eased in the near term, with a 30 day share price return of 5.33% and a 90 day share price return of 0.74%. In contrast, the year to date share price return of...

Moby summary of Annexon, Inc.'s Q2 2026 earnings call

Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the

Annexon, Inc. (NASDAQ:ANNX) shares declined 6.

Annexon recently reported major pipeline milestones, including highly significant Phase 3 data for tanruprubart in Guillain-Barré syndrome and regulatory submissions in Europe, alongside fresh Phase 2 and Phase 3 updates for vonaprument in geographic atrophy presented at a key retina meeting. Together, these developments highlight Annexon’s focus on complement-mediated neuroprotection, with two late-stage programs that could reshape treatment options in rare neurology and...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome. Love described A